About - IBO :

Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. The company was incorporated in 2018 and is based in Houston, Texas.

Employees - 1, CEO - Mr. Frank D. Heuszel Esq., J.D., Sector - Healthcare, Country - US, Market Cap - 13.34M

- Current Price $1.16 - Analyst Target Price $-

Stats & Key Metrics
TickerIBO
Index-
Curent Price 1.16
Change-30.54%
Market Cap13.34M
Average Volume68.67K
Income1.16M
Sales0.00M
Book Value/Share2.72
Cash/Share0.23
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees-
Moving Avg 20days-48.37%
Moving Avg 50days-47.90%
Moving Avg 200days-46.61%
Shares Outstanding11.50M
Earnings Date-
Inst. Ownership0.57%
Key Ratios & Margins
Price/Earnings12.99
Forwad P/E-
PE Growth-
Price/Sales-
Price/Book0.43
Price/Cash5.00
Price/FCF-
Quick Ratio2.79
Current Ratio2.79
Debt/Equity0.26
Return on Assets2.53%
Return on Equity4.01%
Return on Investment2.95%
Gross Margin-
Ops Margin-
Profit Margin-
RSI33.22
BETA(β)-
From 52week Low-4.92%
From 52week High-64.31%
Earnings & Valuation
EPS0.09
EPS next Year-
EPS next Qtr-
EPS this Year-
EPS next 5 Year-
EPS past 5 Year-
Sales past 5 Year0.00%
EPS Y/Y115.92%
Sales Y/Y-100.00%
EPS Q/Q465.54%
Sales Q/Q-
Sales Surprise-
EPS Surprise-
ATR(14)0.48
Perf Week-38.62%
Perf Month-56.23%
Perf Quarter-53.41%
Perf Year-
Perf YTD-56.72%
Target Price-

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer